Baseline characteristics of study patients according to recurrence of atrial fibrillation (AF) after cardioversion
| Characteristic | No AF recurrence (n = 36) | AF recurrence (n = 75) | p Value |
|---|---|---|---|
| Data are mean (SD), number (%), or median (interquartile range). | |||
| CAD, coronary artery disease; CRP, C reactive protein; LA, left atrium; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy. | |||
| Age (years) | 66.5 (12.8) | 67.7 (10.7) | 0.6 |
| Women (n) | 17% (6) | 32% (24) | 0.09 |
| Duration of AF (days) | 203 (345) | 222 (479) | 0.9 |
| CAD (n) | 39% (14) | 40% (30) | 0.9 |
| Hypertension (n) | 71% (26) | 56% (42) | 0.05 |
| LVEF (%) | 0.50 (0.13) | 0.46 (0.13) | 0.2 |
| LVH (n) | 56% (20) | 36% (27) | 0.06 |
| LA diameter (cm) | 4.3 (0.9) | 4.7 (0.9) | 0.06 |
| Antiarrhythmic drug | 0.5 | ||
| Amiodarone | 15 (42%) | 36 (48%) | |
| Flecainide | 12 (33%) | 17 (23%) | |
| Sotalol | 2 (6%) | 11 (15%) | |
| Propafenone | 5 (14%) | 5 (7%) | |
| Dofetilide | 2 (6%) | 3 (4%) | |
| Procainamide | 0 | 1 (1.3%) | |
| Quinidine | 0 | 1 (1.3%) | |
| Disopyramide | 0 | 1 (1.3%) | |
| CRP (mg/l) | |||
| Mean | 3.25 (3.7) | 6.34 (12) | 0.002 |
| Median | 1.81 (0.78–4.17) | 3.95 (2.19–6.13) | 0.002 |